The efficacy of varying doses of venetoclax combined with azacitidine for newly diagnosed adult acute myeloid leukemia in real-world settings: a single-center retrospective analysis
These findings suggest that while both dosing strategies may yield comparable initial responses, long-term outcomes could be adversely influenced by dose reduction, and the 2024 ELN risk classification is more suitable for adult patients with ndAML receiving a reduced-dose regimen of venetoclax and azacitidine.
Authors
- Xi Yang
- Yingxin Sun (ORCID: https://orcid.org/0000-0001-5722-3211)
- Tianzhi Wang (ORCID: https://orcid.org/0000-0001-6838-0757)
- Yang Li (ORCID: https://orcid.org/0000-0003-0735-8446)
- Yanjie Mao (ORCID: https://orcid.org/0000-0002-0931-5354)
- Yaping Zhang (ORCID: https://orcid.org/0000-0002-2408-2405)
- Hong Liu (ORCID: https://orcid.org/0000-0002-7572-6629)
- Yanan Wu (ORCID: https://orcid.org/0000-0003-2667-2772)
- Yifeng Cai
Institutions
- Nantong University (CN)
- Soochow University (CN)
- Affiliated Hospital of Nantong University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Hematology
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1080/16078454.2025.2571248
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00